Dynavax Initiates Pivotal Phase 3 Trial For HEPLISAV(TM), Hepatitis B Vaccine
Thu, 21 Dec 2006 08:00 AM EST
... Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the initiation of a pivotal Phase 3 clinical trial of HEPLISAV, its hepatitis B virus (HBV) vaccine in Canada. Sites in the United States and in Europe are scheduled to participate in the study and are expected to begin dosing patients in early 2007. [click link for full article] ...
Related Topics
- Clinical Trials
- Hepatitis B
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Hepatitis C
- Hepatitis B Vaccine
- Vaccine
- Hepatitis A
- Hepatitis
- Vaccine Side Effects
- Polio Vaccine & Cancer
- Polio Vaccine
- Polio Vaccine & Origin of HIV/AIDS
- Autoimmune Hepatitis
- MMR Vaccine & (Asceptic) Meningitis
- Smallpox Vaccine
- Chickenpox Vaccine
- Pneumococcal Vaccine
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2

Not Signed In -


